The company's discovery services support a wide range of global innovator companies from start-ups to large pharma companies, across a diverse set of therapeutic areas including oncology, CNS, antivirals, and inflammation among others
He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations
He will be stationed at the company HQ in Bengaluru, India
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
The company is doubling its chemistry research capacity that should commission by Q2'FY22
The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.
The facility is expected to be completed in 2024
New manufacturing complex will occupy an overall footprint of approximately 2,000 square meter with six levels of manufacturing space
ICICI Securities expects Hemmo to grow its revenue at a CAGR of 30.0% over FY21E-FY23E
Subscribe To Our Newsletter & Stay Updated
